Clinical Characteristics and Treatment Outcome of Advanced G3 Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)- A Retrospective Analysis Abstract #1781

Introduction: Advanced poorly differentiated GEP-NEC are uncommon neoplasms and treated mainly with platinum-based chemotherapy associated with etoposide.
Aim(s): To assess the clinical characteristics and various predicting factors.
Materials and methods: 10 patients with advanced GEP-NEC, with ki 76 index above 20% treated in our center in the last 8 years were reviewed. Data about site of the primary tumor, presence of metastasis, alkaline phosphatase (ALKP) value and neutrophil/lymphocytes ratio and survival were collected.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Raluca Roxana Grigorescu

To read results and conclusion, please login ...

Further abstracts you may be interested in

#1102 First-Line Chemotherapy in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC): A Retrospective Analysis
Introduction: Gastroenteropancreatic neuroendocrine neoplasia (GEP-NENs) are divided on the basis of Ki67 status into G1-G2 neuroendocrine tumors (NETs) (Ki67 <20%) and neuroendocrine carcinoma (NECs) (Ki67 >20% ). NEC patients generally have a poor prognosis and the first choice treatment is chemotherapy.A cisplatin/etoposide combination is often used as NECs are considered clinically similar to small cell lung cancer (SCLC), but no literature data is available. There is some evidence to suggest that carboplatin may also be effective in metastatic SCLC.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Dr. Alberto Bongiovanni
Keywords: GEP-NEC, chemotherapy
#1308 Systemic Treaments and Prognostic Factors in Chinese Patients with Progressive Advanced Well-differentiated Pancreatic Neuroendocrine Tumors
Introduction: Patients with well-differentiated pancreatic neuroendocrine tumors (pNETs) often present with metastatic disease at the time of diagnosis when curative surgery is not feasible. A variety of systemic therapeutic options exist, but the best strategy is still unknown.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: Yuejuan Cheng
Authors: Cheng Y, Gao H, Bai C M, Ying H, ...
#852 5-FU-based Chemotherapy in Pancreatic Neuroendocrine Neoplasms: Predictive and Prognostic Markers for Treatment und Survival
Introduction: Chemotherapy with 5-FU and Streptozotocin (STZ) represents a standard of care for patients with metastatic pancreatic neuroendocrine neoplasms (PNENs). However, data to identify predictive and prognostic markers are limited.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Chemotherapy
Presenting Author: M.D. Sebastian Krug
Authors: Krug S, Boch M, Rinke A, Nimphius W, ...
Keywords: 5-fluorouracil, DPD, PNEN
#1926 Long-Term Outcomes and Prognostic Factors of Gastroenteropancreatic Neuroendocrine Neoplasms (GEP-NENs): An Update of a Large National Registry (RGETNE)
Introduction: RGETNE is a national hospital-based GEP-NENs registry coordinated by the Spanish multidisciplinary scientific society GETNE.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: MD-PhD Paula Jimenez Fonseca
#598 Pulmonary Neuroendocrine Tumors: Long-Term Survival After Resection and Prognostic Factors
Introduction: Patients with primary pulmonary neuroendocrine tumors (PNT) are often clinically manifested with cough and hemoptysis. Surgery is the preferred treatment.
Conference: 10th Annual ENETS Conference (2013)
Category: Non digestive NETs (bronchial, MTC, pheochromocytoma)
Presenting Author: Jie He
Authors: Chi Y H B L, Gao S G, Du F, Wang J W, ...
Close
Notice
Important Notice:

In preparation of the upcoming ENETS Barcelona 2018 Annual Conference, we have discovered in the world wide web at least one professional entity suggestive of possessing an ENETS mandate for conference registrations. Therefore, we must inform you that 100% of all conference participants are registered through ENETS official website www.enets.org and http://enetsconference.org/. There are no further options to validly register for Barcelona 2018 (or for any other ENETS event).

Please stay away from fraudulent scams abusing the ENETS acronym to register – and charge you above official ENETS conference fees! Such entities, against whom ENETS presses criminal charges, are neither authorized, nor commissioned nor instructed by ENETS to make such representations.